
Loading, please wait...

Loading, please wait...

Oral mucositis remains a debilitating side effect for cancer patients undergoing intensive chemotherapy or radiation. Finding effective pain management strategies is crucial for maintaining quality of life and nutritional intake. A recent clinical study investigated the efficacy of Methylene Blue for oral mucositis pain compared to traditional supportive care mouthwashes. Researchers focused on providing a practical and affordable alternative for hospitalized patients suffering from this condition.
The open-label, non-randomized trial evaluated 43 patients who used either 0.05% Methylene Blue (MB) or a standard medication mouthwash. Patients performed the oral rinse every eight hours for three consecutive days. Both groups showed statistically significant reductions in pain scores. However, the MB group demonstrated a notable decrease in the pain numeric rating scale. Furthermore, this treatment offers a cost-effective option for many oncology departments in resource-limited settings. Consequently, clinicians are looking closer at this dye for its analgesic properties.
Beyond simple pain relief, the trial examined secondary outcomes like daily oral intake volume and opioid requirements. Patients using the Methylene Blue rinse reported better tolerance and management of their symptoms. Additionally, the linear mixed model analysis confirmed that the pain reduction was consistent across the treatment period. Moreover, the study suggests that MB may work through multiple mechanisms, including peripheral neurolysis and inhibition of nitric oxide. Ultimately, healthcare providers should consider these findings when selecting supportive care options for oral complications in cancer therapy.
The study utilized a 0.05% concentration of Methylene Blue mouthwash for the participants to ensure safety and efficacy.
In this clinical trial, patients performed the oral rinse every 8 hours for a duration of three days to achieve optimal pain reduction.
Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Karow J et al. Methylene Blue Mouthwash for Oral Mucositis Pain in Cancer: An Open-Label, Non-Randomized Study. J Pain Palliat Care Pharmacother. 2026 Apr 11. doi: 10.1080/15360288.2026.2655779. PMID: 41964386.
Roldan CJ, et al. Methylene Blue for the Treatment of Intractable Pain From Oral Mucositis Related to Cancer Treatment: An Uncontrolled Cohort. J Natl Compr Canc Netw. 2021;19(5):521-527.
Rondelli E, et al. Methylene blue in chemoradiotherapy-induced oral mucositis: Systematic review and meta-analysis. J Cancer Res Ther. 2026;22(1):13-19.
"
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A study shows Methylene Blue mouthwash (0.05%) significantly reduces oral mucositis pain in cancer patients compared to standard supportive care....
6 months ago

A retrospective cohort study reveals that frailty quadruples the odds of pressure injuries in hospitalized older adults. Integrating the Clinical Frailty Scale with comprehensive geriatric care is crucial for identifying vulnerability early and implementing targeted multidisciplinary prevention.
Today

Occult maternal malignancy accounts for 3.82% of persistent unreportable NIPT results with genomic noise. Multiple chromosomal aberrations, notably on chromosome 18, warrant thorough oncological evaluation and whole-body MRI to ensure timely maternal diagnosis while preserving fetal care.
Today

This article reviews the forensic and clinical complexities of acute myocarditis arising on left ventricular hypertrophy in children, highlighting early diagnostic red flags and multidisciplinary postmortem autopsy protocols.
Today

A randomized controlled trial demonstrates that an eight-week dual-task training intervention significantly improves static and dynamic postural control over standard balance exercises in individuals with chronic ankle instability, addressing critical neurocognitive deficits during athletic and daily activities.
Today

A retrospective cohort study of 7,716 ICU patients from the MIMIC-IV database demonstrates that Gradient Boosting Decision Trees significantly outperform traditional SOFA scores in predicting in-hospital mortality among patients with sepsis and diabetes, with SHAP analysis providing clinical interpretability.
Today